iCoreConnect Provides Update on Post Business Combination Share Exchange
29 Agosto 2023 - 11:00PM
via NewMediaWire – iCoreConnect, Inc.
(Nasdaq: ICCT) (“iCore” or
the “Company”), a cloud-based software and technology company
focused on increasing workflow productivity and customer
profitability through its enterprise and healthcare workflow
platform, today provided an update on recent trading activity
following the close of its business combination with FG Merger
Corp. (“FGMC” (Nasdaq: FGMC), a special purpose acquisition
corporation. Today, trading of ICCT’s securities was halted on
Nasdaq when it was identified that certain shares did not convert
using the post-business combination exchange ratio. The situation
has been corrected and the Company will resume trading at market
open on Wednesday, August 30, 2023.
Shareholders seeking additional information on how this may
impact their individual positions should contact their respective
brokerage firms.
About iCoreConnect, Inc.
iCoreConnect, Inc. is a cloud-based software and technology
company focused on increasing workflow productivity and practice
profitability through its enterprise and healthcare workflow
platform of applications and services. iCoreConnect is most notably
known for its innovation in solving healthcare business problems.
iCoreConnect’s philosophy places a high value on customer feedback,
allowing iCoreConnect to respond to the market’s needs.
iCoreConnect touts a platform of 16 SaaS enterprise solutions and
more than 100 product endorsements with state or regional
healthcare associations across the United States.
Forward-Looking Statements
Some of the statements in this release are forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, Section 21E of the Securities Exchange Act of 1934 and the
Private Securities Litigation Reform Act of 1995, which involve
risks and uncertainties. Forward-looking statements in this press
release include, without limitation, the Company’s revenue and
annualized recurring revenue estimates for 2023, the Company’s
ability to grow opportunities within ePrescription and insurance
verification, and the Company's ability to continue to expand its
reach into medical customers. Although the Company believes that
the expectations reflected in such forward-looking statements are
reasonable as of the date made, expectations may prove to have been
materially different from the results expressed or implied by such
forward-looking statements. The Company has attempted to identify
forward-looking statements by terminology including ‘believes,’
‘estimates,’ ‘anticipates,’ ‘expects,’ ‘plans,’ ‘projects,’
‘intends,’ ‘potential,’ ‘may,’ ‘could,’ ‘might,’ ‘will,’ ‘should,’
‘approximately’ or other words that convey uncertainty of future
events or outcomes to identify these forward-looking statements.
These statements are only predictions and involve known and unknown
risks, uncertainties, and other factors, including those discussed
under Item 1A. “Risk Factors” in the Company’s most recently filed
Form 10-K filed with the Securities and Exchange Commission (“SEC”)
and updated from time to time in its Form 10-Q filings and in its
other public filings with the SEC. Any forward-looking statements
contained in this release speak only as of its date. The Company
undertakes no obligation to update any forward-looking statements
contained in this release to reflect events or circumstances
occurring after its date or to reflect the occurrence of
unanticipated events.
Investor Contacts:Davis Snyder or Nick
Nelson312-445-2870ICCT@alpha-ir.com
iCoreConnect (NASDAQ:ICCT)
Gráfico Histórico do Ativo
De Dez 2024 até Jan 2025
iCoreConnect (NASDAQ:ICCT)
Gráfico Histórico do Ativo
De Jan 2024 até Jan 2025